" Avicanna (TSX:AVCN) enters an agreement with Pioneer Knop Laboratorios S.A.

Through its subsidiary Santa Marta Golden Hemp, Avicanna (AVCN) has entered into a supply agreement with Chilean pharmaceutical company Knop Laboratorios S.A.

" BioSyent (TSXV:RX) renews NCIB

BioSyent (RX) has announced that the TSX Venture Exchange has accepted the company’s Notice of Intention to renew its NCIB.

" Algernon Pharmaceuticals (CSE:AGN) completes manufacturing of DMT and appoints UK stroke experts for phase 2 trials

Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.

" Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.
The Market Herald Video

" NervGen Pharma (TSXV:NGEN) closes private placement

NervGen Pharma (NGEN) has closed a non-brokered private placement for aggregate gross proceeds of $2,321,075.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) reports CBD in mice’s brains 41 days after injection

Innocan Pharma Corp. (INNO) shows results from a study using its CBD-Loaded Liposome Platform Technology (LPT) delivery system.

" Marvel Biosciences (TSXV:MRVL) updates the status of its MB-204 manufacturing efforts

Marvel Biosciences Corp. (MRVL) reports a successful process development of the active pharmaceutical ingredient of its lead drug MB-204.

" Innocan Pharma Corporation (CSE:INNO) announces $8.2 million private placement with investors

Today Innocan Pharma (INNO) has entered into securities purchase agreements for a private placement of its common shares to institutional investors.
The Market Herald Video

" MYND Life Sciences (CSE:MYND) announces $3M convertible debenture unit offering

MYND Life Sciences (MYND) entered into a non-brokered private placement offering of debenture units with an institutional investor.

" Satellos Bioscience (TSXV:MSCL) announces joint development agreement with NW PharmaTech

Satellos Bioscience (MSCL) subsidiary Amphotericin B Technologies has entered into a joint development agreement with NW PharmaTech.

" Claritas (TSXV:CLAS) closes first tranche of private placement with Obsidian Global GP

Claritas Pharmaceuticals (CLAS) will close the first tranche of a brokered private placement offering with Obsidian Global Partners, LLC.

" IntelGenx (TSXV:IGX) closes notes offering

IntelGenx (IGX) has announced the closing of a private placement of 8 per cent convertible notes due July 31, 2025.
BioCure Technology - Björn Cochlovius Ph.D. President

" BioCure Technology Inc. (CSE:CURE) provides corporate updates

BioCure Technology (CURE) has appointed a new president, a Capital Markets Advisor and granted stock options to directors, employees and consultants.

" Medexus (TSX:MDP) appoints new Chief Financial Officer

Medexus Pharmaceuticals (MDP) has appointed Marcel Konrad as Chief Financial Officer, effective immediately.

" EnWave (TSXV:ENW) and AstraZeneca to test REV technology for pharmaceutical dehydration

EnWave Corporation (ENW) has signed a material transfer agreement with MedImmune Limited, an affiliate of AstraZeneca AB.

" BetterLife Pharma (CSE:BETR) closes $2.61 Million public offering

BetterLife Pharma (BETR) has closed its marketed public offering.
Featured Video Play Icon

" InvestmentPitch Media video discusses the ruling by the D.C. Circuit Court of Appeals qualifying Voyageur Pharmaceuticals’ (TSXV:VM) products as devices

The D.C. Circuit Court of Appeals has concluded that the radiographic contrast agent barium sulfate qualifies as a device rather than a drug.

" Claritas (TSXV:CLAS) partners with CMAX Clinical Research for phase 1 R-107 clinical study

Claritas Pharmaceuticals (CLAS) has entered into an agreement with CMAX Clinical Research Pty Ltd. to conduct a Phase 1 clinical study of R-107.